AbbVie lowers its profit forecast for the second quarter and full year of 2021.

On July 4th, Guolong News reported that American pharmaceutical company AbbVie lowered its profit forecast for this year because the group needs to account for additional research and development expenses totaling $937 million for an acquisition activity. The company stated that according to the latest internal estimate, this quarter must include additional expenses related to acquisitions, patent agreements, and joint research, totaling $937 million. The latest estimate by the group is that the adjusted earnings per share for the second quarter is expected to be between $2.53 and $2.57, previously $3.05 to $3.09; the adjusted earnings per share for this year will be between $10.61 and $10.81, previously $11.1.

Gelonghui Finance09:00

AbbVie (ABBV.US) has lowered its second quarter and full-year earnings forecasts.

Regulatory documents show that American pharmaceutical company AbbVie(ABBV.US) will adjust its full-year earnings per share forecast to $10.61-$10.81, previously forecasted as $11.13-$11.33, while analysts are expecting $11.25 per share. AbbVie also lowered its adjusted earnings per share forecast for the second quarter from $3.05-$3.09 to $2.53-$2.57 due to $937 million in expenses related to cooperation, licensing agreements, and other asset acquisitions during the quarter. AbbVie is scheduled to release its second-quarter results on July 25th.

AASTOCKS08:18

AbbVie Q2 IPR&D Expenses to Lower EPS by $0.52

Seeking Alpha02:55

Express News | Abbvie Inc FY2024 Shr View $11.25 -- LSEG IBES Data

Breakings02:11

Express News | Abbvie -Q2 2024 Adjusted Diluted Earnings per Share Guidance Range, Including Impact of Q2 2024 Acquired Ipr&D, Milestones Expense $2.53 - $2.57

Breakings02:10

Express News | Abbvie: Earnings for Q2 of 2024 Expected to Include Acquired Ipr&D and Milestones Expense of $937 Mln on Pre-Tax Basis

Breakings02:10